FOXM1 and glioblastoma: Recently, a study has demonstrated that the m6A demethylase ALKBH5 served as a negative prognostic biomarker for GBM patients and maintained the tumorigenicity of glioblastoma stem cell–like cells by activating FOXM1 expression and cell growth (Zhang et al., 2017).